Ken A Brameld

3PUBLICATIONS
4CO-AUTHORS
Tumour immunologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (3)

|Mar 18, 2022
Discovery of Reversible Covalent Bruton's Tyrosine Kinase Inhibitors PRN473 and PRN1008 (Rilzabrutinib).

Timothy D Owens, Ken A Brameld, Erik J Verner

|Mar 06, 2021
Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease.

Claire L Langrish, J Michael Bradshaw, Michelle R Francesco

|Jul 01, 2017
Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors.

Ken A Brameld, Timothy D Owens, Erik Verner

Pageof 1

Frequent Collaborators

2 joint publications

Timothy D Owens

1 joint publications

Yan Xing

1 joint publications

Catherine Outerbridge

1 joint publications

Stephen D White